Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Prashant Tembhare, MD, Gaurav Narula, MD, Gaurav Chatterjee, MD, Twinkle Khanka, Mahima Sanyal, Sitaram Ghogale, Nikhil Patkar, MD, Nilesh Deshpande, Yajamanam Badrinath, Sumeet Gujral, MD, Shripad Banavali, MD, Papagudi Ganesan Subramanian, MD

Blood (2019) 134 (Supplement_1): 2585.

https://doi.org/10.1182/blood-2019-128347

Published: 2019

Journal Articles

Metronomic Chemotherapy Is Effective and Well Tolerated in Relapsed/Refractory Elderly Patients with Aggressive B- and T-Cell Lymphomas

Maria Christina Cox, MDPhD, Elena Cavalieri, MD, maria Paola Bianchi, Raffaele Porrini, MD, Virginia Naso, MD, Marco di Girolamo, MD, Daniela Prosperi, Francesca di Landro, Agostino Tafuri, MD

Blood (2015) 126 (23): 5080.

https://doi.org/10.1182/blood.V126.23.5080.5080

Published: 2015

Journal Articles

Sorafenib Combined with Non-Conventional Chemotherapy Produces Deep Remissions in FMS-like Tyrosine Kinase-3 Gene / Internal Tandem Duplication Positive (FLT-3 / ITD+) Acute Myeloid Leukemia (AML) Patients

Shripad Banavali, MD, Nirav Thacker, DM, Brijesh Arora, DM, Gaurav Narula, MD, Maya Prasad, MD, Nirmalya Pradhan, MD, Saroj Panda, DM, Nikhil Patkar, MD, Prashant Tembhare, MD, Papagudi Ganesan Subramanian, MD

Blood (2015) 126 (23): 4939.

https://doi.org/10.1182/blood.V126.23.4939.4939

Published: 2015

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

Journal Articles

Single Agent Metronomic Cyclophosphamide in Refractory,Non-Hodgkin's Lymphoma.

Caroline Hamm, MD, Sindu M. Kanjeekal, MD, FRCP(C), John Mathews, MD, FRCP(C), Yasmin Alam, Sam Yoshida, Tarek Elfiki

Blood (2009) 114 (22): 4776.

https://doi.org/10.1182/blood.V114.22.4776.4776

Published: 2009

Journal Articles

A Novel, Efficacious Therapeutic Approach to Patients with Acute Promyelocytic Leukemia (APL) Using Differentiating Agent and Metronomic Chemotherapy (CT).

Shripad D. Banavali, MD, Lovenish Goyal, MD, Reena Nair, MD, Ghanashyam Biswas, MD, Pratibha Amare-Kadam, PhD, Chanda Baisane, MSc, Shashikant Mahadik, MSc, Sumit Gujral, MD, Narayan Karanth, MD, Brijesh Arora, MD, Roshni Bhagwat, MD, Purna Kurkure, MD, Purvish Parikh, MD, PhD

Blood (2005) 106 (11): 900.

https://doi.org/10.1182/blood.V106.11.900.900

Published: 2005

Journal Articles

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

Yuval Shaked, Urban Emmenegger, Shan Man, Dave Cervi, Francesco Bertolini, Yaacov Ben-David, Robert S. Kerbel

Blood (2005) 106 (9): 3058–3061.

https://doi.org/10.1182/blood-2005-04-1422

Published: 2005

Journal Articles

High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL.

Rena Buckstein, M. Crump, Y. Shaked, D. Spaner, E. Piliotis, K. Imrie, R. Nayar, C. Foden, R. Turner, D. Taylor, S. Man, S. Baruchel, D. Stempak, I. Quirt, J. Sturgeon, F. Bertolini, R.S. Kerbel

Blood (2004) 104 (11): 4622.

https://doi.org/10.1182/blood.V104.11.4622.4622

Published: 2004

NARROW

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Metronomic Chemotherapy Is Effective and Well Tolerated in Relapsed/Refractory Elderly Patients with Aggressive B- and T-Cell Lymphomas

Sorafenib Combined with Non-Conventional Chemotherapy Produces Deep Remissions in FMS-like Tyrosine Kinase-3 Gene / Internal Tandem Duplication Positive (FLT-3 / ITD+) Acute Myeloid Leukemia (AML) Patients

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Single Agent Metronomic Cyclophosphamide in Refractory,Non-Hodgkin's Lymphoma.

A Novel, Efficacious Therapeutic Approach to Patients with Acute Promyelocytic Leukemia (APL) Using Differentiating Agent and Metronomic Chemotherapy (CT).

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only